Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Illumina, Inc.
ILMN
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $27.8B
$188.79
▲ +2.66%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$88.00 - $189.36
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 83.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Technological leadership in genetic sequencing
- Comprehensive genomic solution ecosystem
- Strong intellectual property portfolio
- Global market penetration
Bear Case
2 risks
- Average volatility.
- Significant premium - growth priced in
Growth
Stable outlook
Precision medicine expansion
Value
Significant premium - growth priced in
Momentum
Hot
+44.4% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ILMN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 30, 2026
APR 30, 2026
Reported EPS of $1.15 vs $1.05 consensus (+9.5% surprise). Revenue of $1.1B vs $1.1B expected (+1.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+9.5%
Next: Jul 30, 2026
Revenue trend · last 8Q
—
—
-2%
-3%
-5%
+0%
+5%
+5%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.1B
$1.1B
$1.1B
$1.0B
$1.1B
$1.1B
$1.2B
$1.1B
Margins · last 8Q
Gross
68.2%
Operating
21.3%
Profit
12.3%
Wall Street consensus
9 analysts · 44% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
44%
Hold
33%
Sell
22%
Median Price Target
$155.00
▼ -17.9% vs $188.79
Latest: Piper Sandler · Jul 1, 2026
5 analysts covering